ASCO26: DNA Test Could Spare Breast Cancer Patients Chemo
8 Articles
8 Articles
A new genome test could lead to people with breast cancer undergoing unnecessary chemotherapy less often. This is the conclusion of a study led by University College London. The research was presented on Saturday at the annual meeting of the American Society of Clinical Oncology in Chicago, the world's largest cancer conference. More than 4,000 patients recently diagnosed with hormone-positive breast cancer, the most common form of breast cancer…
Breast cancer is the most common type of cancer in Icelandic women and accounts for nearly a third of all cancers diagnosed. The results of a new international study indicate that genetic tests can be used to assess the likelihood of benefit from chemotherapy. Such genetic tests are used here and the director of the Icelandic Cancer Society says that Icelandic patients benefit from them. A team at the University of London conducted the study, wh…
Breast cancer is the most common cancer in women worldwide. After surgery, stressful chemotherapy is often followed — even in patients with little or no benefit at all. A genomic test could change this. At the annual congress of the American Society of Clinical Oncology (ASCO) in Chicago, the results of the international phase III study OPTIMA were presented. More than 4,400 patients with hormonal-sensitive, HER2-negative breast cancer in the ea…
Presented at the annual conference of the American Society of Clinical Oncology, these results are part of a major evolution in oncology: avoid unnecessary treatments when the biology of the tumor shows that they bring little benefit. The Prosigna test does not replace breast cancer treatments. It serves to better decide which patients can avoid chemotherapy after surgery. Breast cancer: Prosigna refines the treatment decision In breast cancer, …
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
